NZ232642A - Compositions suitable for use in gelatin capsules comprising ranitidine and a fat or oil - Google Patents
Compositions suitable for use in gelatin capsules comprising ranitidine and a fat or oilInfo
- Publication number
- NZ232642A NZ232642A NZ232642A NZ23264290A NZ232642A NZ 232642 A NZ232642 A NZ 232642A NZ 232642 A NZ232642 A NZ 232642A NZ 23264290 A NZ23264290 A NZ 23264290A NZ 232642 A NZ232642 A NZ 232642A
- Authority
- NZ
- New Zealand
- Prior art keywords
- filling
- ranitidine
- pharmaceutical composition
- mixture
- gelatin capsules
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims description 33
- 229960000620 ranitidine Drugs 0.000 title claims description 23
- 239000007903 gelatin capsule Substances 0.000 title claims description 22
- VMXUWOKSQNHOCA-LCYFTJDESA-N ranitidine Chemical compound [O-][N+](=O)/C=C(/NC)NCCSCC1=CC=C(CN(C)C)O1 VMXUWOKSQNHOCA-LCYFTJDESA-N 0.000 title 1
- VMXUWOKSQNHOCA-UKTHLTGXSA-N ranitidine Chemical compound [O-][N+](=O)\C=C(/NC)NCCSCC1=CC=C(CN(C)C)O1 VMXUWOKSQNHOCA-UKTHLTGXSA-N 0.000 claims description 26
- 239000011159 matrix material Substances 0.000 claims description 22
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 19
- 239000000194 fatty acid Substances 0.000 claims description 19
- 229930195729 fatty acid Natural products 0.000 claims description 19
- 239000002775 capsule Substances 0.000 claims description 17
- 239000008194 pharmaceutical composition Substances 0.000 claims description 17
- 150000003839 salts Chemical class 0.000 claims description 17
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 15
- 239000004094 surface-active agent Substances 0.000 claims description 13
- 108010010803 Gelatin Proteins 0.000 claims description 11
- 229920000159 gelatin Polymers 0.000 claims description 11
- 239000008273 gelatin Substances 0.000 claims description 11
- 235000019322 gelatine Nutrition 0.000 claims description 11
- 235000011852 gelatine desserts Nutrition 0.000 claims description 11
- 229960001520 ranitidine hydrochloride Drugs 0.000 claims description 11
- GGWBHVILAJZWKJ-KJEVSKRMSA-N ranitidine hydrochloride Chemical compound [H+].[Cl-].[O-][N+](=O)\C=C(/NC)NCCSCC1=CC=C(CN(C)C)O1 GGWBHVILAJZWKJ-KJEVSKRMSA-N 0.000 claims description 11
- 150000004665 fatty acids Chemical class 0.000 claims description 9
- 239000002480 mineral oil Substances 0.000 claims description 9
- 239000012188 paraffin wax Substances 0.000 claims description 7
- 239000004480 active ingredient Substances 0.000 claims description 6
- 239000004615 ingredient Substances 0.000 claims description 6
- 235000010446 mineral oil Nutrition 0.000 claims description 6
- 150000003626 triacylglycerols Chemical class 0.000 claims description 6
- 239000012458 free base Substances 0.000 claims description 5
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims description 4
- 125000005456 glyceride group Chemical group 0.000 claims description 4
- 235000010445 lecithin Nutrition 0.000 claims description 4
- 239000000787 lecithin Substances 0.000 claims description 4
- 229940067606 lecithin Drugs 0.000 claims description 4
- 239000008240 homogeneous mixture Substances 0.000 claims description 3
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 239000002687 nonaqueous vehicle Substances 0.000 claims description 2
- 101100536354 Drosophila melanogaster tant gene Proteins 0.000 claims 1
- 230000002209 hydrophobic effect Effects 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 239000007788 liquid Substances 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000003801 milling Methods 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical class OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 235000013162 Cocos nucifera Nutrition 0.000 description 1
- 244000060011 Cocos nucifera Species 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 239000004264 Petrolatum Substances 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 239000013011 aqueous formulation Substances 0.000 description 1
- 125000003289 ascorbyl group Chemical class [H]O[C@@]([H])(C([H])([H])O*)[C@@]1([H])OC(=O)C(O*)=C1O* 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 229940088679 drug related substance Drugs 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 229940066842 petrolatum Drugs 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- -1 polysorbate 80) or Chemical class 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 125000000446 sulfanediyl group Chemical group *S* 0.000 description 1
- 229910021653 sulphate ion Inorganic materials 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB898904182A GB8904182D0 (en) | 1989-02-23 | 1989-02-23 | Pharmaceutical compositions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ232642A true NZ232642A (en) | 1992-07-28 |
Family
ID=10652220
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ232642A NZ232642A (en) | 1989-02-23 | 1990-02-22 | Compositions suitable for use in gelatin capsules comprising ranitidine and a fat or oil |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US5028432A (enExample) |
| JP (1) | JP2856817B2 (enExample) |
| KR (1) | KR940006271B1 (enExample) |
| AT (1) | AT401727B (enExample) |
| AU (1) | AU629303B2 (enExample) |
| BE (1) | BE1003123A3 (enExample) |
| CA (1) | CA2010692C (enExample) |
| CH (1) | CH680567A5 (enExample) |
| CY (1) | CY1734A (enExample) |
| DE (1) | DE4005650C2 (enExample) |
| DK (1) | DK170209B1 (enExample) |
| FR (1) | FR2643263B1 (enExample) |
| GB (2) | GB8904182D0 (enExample) |
| HK (1) | HK89493A (enExample) |
| HU (1) | HU211930A9 (enExample) |
| IE (1) | IE63179B1 (enExample) |
| IL (1) | IL93490A (enExample) |
| IT (1) | IT1240768B (enExample) |
| LU (1) | LU87681A1 (enExample) |
| NL (1) | NL193267C (enExample) |
| NZ (1) | NZ232642A (enExample) |
| PH (1) | PH26972A (enExample) |
| SA (1) | SA90100287B1 (enExample) |
| SE (1) | SE512412C2 (enExample) |
| ZA (1) | ZA901348B (enExample) |
| ZW (1) | ZW1790A1 (enExample) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU8546591A (en) * | 1990-09-13 | 1992-04-15 | Smithkline Beecham Corporation | Non-aqueous liquid oral suspensions |
| US5571533A (en) * | 1992-02-07 | 1996-11-05 | Recordati, S.A., Chemical And Pharmaceutical Company | Controlled-release mucoadhesive pharmaceutical composition for the oral administration of furosemide |
| WO1994008576A1 (en) * | 1992-10-16 | 1994-04-28 | Glaxo Group Limited | Taste-masking compositions of ranitidine |
| US5433951A (en) * | 1993-10-13 | 1995-07-18 | Bristol-Myers Squibb Company | Sustained release formulation containing captopril and method |
| DE4341310A1 (de) * | 1993-12-03 | 1995-06-08 | Hexal Pharma Gmbh | Tablette oder Kapsel mit einem Gehalt an stabilem Ranitidinhydrochlorid Form 1 |
| GB9325445D0 (en) | 1993-12-13 | 1994-02-16 | Cortecs Ltd | Pharmaceutical formulations |
| US5407687A (en) * | 1994-02-22 | 1995-04-18 | Glaxo Inc. | Ranitidine solid dosage form |
| GB9405304D0 (en) * | 1994-03-16 | 1994-04-27 | Scherer Ltd R P | Delivery systems for hydrophobic drugs |
| US5538737A (en) * | 1994-11-30 | 1996-07-23 | Applied Analytical Industries, Inc. | Oral compositions of H2 -antagonists |
| GB9705813D0 (en) * | 1997-03-20 | 1997-05-07 | Smithkline Beecham Plc | Novel compositions |
| AR013261A1 (es) * | 1997-08-01 | 2000-12-13 | Smithkline Beecham Corp | Formulaciones farmaceuticas para analogos de camptotecina en capsula de gelatina |
| US7011846B2 (en) * | 2001-12-21 | 2006-03-14 | Shire Laboratories, Inc. | Oral capsule formulation with increased physical stability |
| JP2006518380A (ja) * | 2003-01-31 | 2006-08-10 | スミスクライン・ビーチャム・コーポレイション | 固体分散体組成物 |
| CN1863510A (zh) | 2003-08-13 | 2006-11-15 | 比奥孔有限公司 | 用于治疗剂的微－粒子脂肪酸盐固体剂量制剂 |
| EP2585025B2 (en) | 2010-06-23 | 2022-10-26 | Colgate-Palmolive Company | Therapeutic oral composition |
| PH12013501079A1 (en) | 2010-12-20 | 2019-08-07 | Colgate Palmolive Co | Gelatin encapsulated oral care composition containing dental occlusion actives, hydrophobic viscosity modifier and oil carrier |
| CN103260466B (zh) | 2010-12-20 | 2016-08-17 | 高露洁-棕榄公司 | 含有亲水性活性物质、疏水性结构化剂和油载体的明胶包囊的口腔护理组合物 |
| WO2012087281A1 (en) | 2010-12-20 | 2012-06-28 | Colgate-Palmolive Company | Non-aqueous oral care composition containing dental occlusion actives |
| CA3042466A1 (en) * | 2016-11-01 | 2018-05-11 | Johnson & Johnson Consumer Inc. | Liquid oral pharmaceutical dosage form |
| CN109010303B (zh) * | 2017-06-09 | 2021-05-07 | 苏州科伦药物研究有限公司 | 一种盐酸雷尼替丁胶囊的工业制备方法 |
| KR102108153B1 (ko) * | 2017-07-05 | 2020-05-07 | (주)동구바이오제약 | 생체 이용률 및 안정성이 개선된 레티노이드를 함유하는 약제학적 조성물 |
| KR20210057756A (ko) * | 2018-09-07 | 2021-05-21 | 알.피.쉐러 테크놀러지즈 엘엘씨 | 경화 및 낮은 hlb 계면 활성제(들)의 첨가를 통한 고체 또는 반고체 지질 기반 제형 안정화 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3374146A (en) * | 1966-04-18 | 1968-03-19 | American Cyanamid Co | Sustained release encapsulation |
| DE2360796B2 (de) * | 1973-12-06 | 1977-06-02 | Edelfettwerke Werner Schlüter, 2000 Hamburg; Glyco Iberica S.A., Gava, Barcelona (Spanien) Vti: Hegel, K.Th., Dr.; Dickel, K., Dipl.-Ing.; Pat.-Anwälte, 2000 Hamburg und 8000 München | Arzneimittel mit verzoegerter abgabe des wirkstoffs im darm |
| GB1565966A (en) * | 1976-08-04 | 1980-04-23 | Allen & Hanburys Ltd | Aminoalkyl furan derivatives |
| IT1090703B (it) * | 1976-12-03 | 1985-06-26 | Scherer Ltd R P | Perfezionamento nelle composizioni utili quali veicolo per farmaci |
| JPS5919524B2 (ja) * | 1976-12-17 | 1984-05-07 | 中外製薬株式会社 | 安定な１α−ヒドロキシビタミンＤ類含有製剤 |
| GB1572226A (en) * | 1977-11-03 | 1980-07-30 | Hoechst Uk Ltd | Pharmaceutical preparations in solid unit dosage form |
| JPS55136219A (en) * | 1979-04-11 | 1980-10-23 | Sumitomo Chem Co Ltd | Diazepam oily drug |
| EP0040489A1 (en) * | 1980-05-17 | 1981-11-25 | FISONS plc | Mixtures, salts, packages and pharmaceutical compositions containing 5-(2-hydroxypropoxy)-4-oxo-8-propyl-4H-1-benzopyran-2-carboxylic acid or a derivative thereof and an H2 receptor antagonist antihistamine |
| CY1306A (en) * | 1980-10-01 | 1985-12-06 | Glaxo Group Ltd | Aminoalkyl furan derivative |
| IL63968A (en) * | 1980-10-01 | 1985-10-31 | Glaxo Group Ltd | Form 2 ranitidine hydrochloride,its preparation and pharmaceutical compositions containing it |
| DE3264782D1 (en) * | 1981-10-16 | 1985-08-22 | Sanol Arznei Schwarz Gmbh | Medicinal formulation |
| JPS58174308A (ja) * | 1982-04-06 | 1983-10-13 | Fujimoto Seiyaku Kk | レクタルカプセル坐剤 |
| BE896711A (fr) * | 1982-05-14 | 1983-09-01 | Richter Gedeon Vegyeszet | Compositions pharmaceutiques anti-ulceres. |
| DE3237814A1 (de) * | 1982-10-12 | 1984-04-12 | Warner-Lambert Co., 07950 Morris Plains, N.J. | Wasserfreie emulsionen und verwendung derselben |
| WO1985000516A1 (en) * | 1983-08-01 | 1985-02-14 | R. P. Scherer Corporation | Sustained release method and product |
| GB8903804D0 (en) * | 1989-02-20 | 1989-04-05 | Sandoz Ltd | Improvements in or relating to organic compounds |
| GB8426738D0 (en) * | 1984-10-23 | 1984-11-28 | Scras | Pyridine derivatives |
| GB8516083D0 (en) * | 1985-06-25 | 1985-07-31 | Glaxo Group Ltd | Heterocyclic compounds |
| JPH07549B2 (ja) * | 1986-07-03 | 1995-01-11 | ゼリア新薬工業株式会社 | 軟カプセル充填用組成物 |
| DE3629386A1 (de) * | 1986-08-29 | 1988-03-03 | Scherer Gmbh R P | Gelatinekapseln und verfahren zu ihrer herstellung |
| IL90245A (en) * | 1988-05-11 | 1994-04-12 | Glaxo Group Ltd | Resin adsorbate comprising ranitidine together with a synthetic cation exchange resin, its preparation and pharmaceutical compositions containing it |
| NL8902338A (nl) * | 1988-09-20 | 1990-04-17 | Glaxo Group Ltd | Farmaceutische preparaten. |
-
1989
- 1989-02-23 GB GB898904182A patent/GB8904182D0/en active Pending
-
1990
- 1990-02-21 LU LU87681A patent/LU87681A1/fr unknown
- 1990-02-21 ZW ZW17/90A patent/ZW1790A1/xx unknown
- 1990-02-22 CA CA002010692A patent/CA2010692C/en not_active Expired - Lifetime
- 1990-02-22 BE BE9000197A patent/BE1003123A3/fr not_active IP Right Cessation
- 1990-02-22 FR FR909002187A patent/FR2643263B1/fr not_active Expired - Lifetime
- 1990-02-22 CH CH569/90A patent/CH680567A5/fr not_active IP Right Cessation
- 1990-02-22 AU AU50073/90A patent/AU629303B2/en not_active Expired
- 1990-02-22 ZA ZA901348A patent/ZA901348B/xx unknown
- 1990-02-22 NZ NZ232642A patent/NZ232642A/en unknown
- 1990-02-22 DE DE4005650A patent/DE4005650C2/de not_active Expired - Lifetime
- 1990-02-22 KR KR1019900002250A patent/KR940006271B1/ko not_active Expired - Lifetime
- 1990-02-22 JP JP2042288A patent/JP2856817B2/ja not_active Expired - Lifetime
- 1990-02-22 PH PH40086A patent/PH26972A/en unknown
- 1990-02-22 US US07/482,903 patent/US5028432A/en not_active Expired - Lifetime
- 1990-02-22 IL IL9349090A patent/IL93490A/en not_active IP Right Cessation
- 1990-02-22 GB GB9004016A patent/GB2229094B/en not_active Expired - Lifetime
- 1990-02-22 AT AT0042190A patent/AT401727B/de not_active IP Right Cessation
- 1990-02-22 IE IE65190A patent/IE63179B1/en not_active IP Right Cessation
- 1990-02-22 DK DK048090A patent/DK170209B1/da not_active IP Right Cessation
- 1990-02-22 NL NL9000428A patent/NL193267C/nl not_active IP Right Cessation
- 1990-02-22 IT IT47659A patent/IT1240768B/it active IP Right Grant
- 1990-02-22 SE SE9000625A patent/SE512412C2/sv unknown
- 1990-06-23 SA SA90100287A patent/SA90100287B1/ar unknown
-
1993
- 1993-08-26 HK HK894/93A patent/HK89493A/xx not_active IP Right Cessation
-
1994
- 1994-05-06 CY CY173494A patent/CY1734A/en unknown
-
1995
- 1995-06-29 HU HU95P/P00543P patent/HU211930A9/hu unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5028432A (en) | Pharmaceutical capsules containing panetidine | |
| KR910000655B1 (ko) | 신규 형태의 연질캡슐 제조방법 | |
| PT2279729T (pt) | Preparações de libertação controlada | |
| EP0734253A1 (en) | Biphasic capsule formulation | |
| EP0173293B1 (en) | Hot melt antihistamine formulations | |
| JPH0816051B2 (ja) | 徐放性坐剤 | |
| US5175002A (en) | Amantadine hydrochloride syspension with enhanced dissolution characteristics for use in soft gelatin capsules | |
| HUP0100580A2 (hu) | Oldott paroxetint tartalmazó készítmények | |
| US5275821A (en) | Amantadine hydrochloride suspension with enhanced dissolution characteristics for use in soft gelatin capsules | |
| US20040146537A1 (en) | Oily wax matrix suspension formulation comprising pharmacologically active agents | |
| EP0431659B1 (en) | Pharmaceutical compositions of tebufelone | |
| JP2001048809A (ja) | ポリグリセリンベヘニン酸エステル含有徐放性坐剤 | |
| CA2179041C (en) | Biphasic capsule formulation | |
| JPS61200909A (ja) | 経口投与持続性カプセル剤 | |
| JPS59106418A (ja) | ニフエジピン製剤 | |
| JP2001048778A (ja) | 油脂含有徐放性坐剤 | |
| MXPA06000100A (en) | Controlled release preparations | |
| CZ20001876A3 (cs) | Prostředky obsahující rozpuštěný paroxetin |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RENW | Renewal (renewal fees accepted) |